Oraya Therapeutics

An Exciting New Treatment Option

Please check this section frequently for updates on news announcements, industry events, and for our latest media resources.

Upcoming Events

British and Eire Association of Vitreoretinal Surgeons (BEAVRS)
November 20-21, 2014 | Edinburgh, United Kingdom

Latest Press Releases

Saturday, September 13, 2014 | Oraya Therapeutics Inc. announced today that full results of three-year safety follow-up data from the INTREPID study of Oraya Therapy™ for wet age-related macular degeneration (AMD) further demonstrated a favorable safety profile and also showed that there was no significant difference in vision outcomes in patients treated with Oraya Therapy compared with those receiving anti-vascular endothelial growth factor (anti-VEGF) injections alone. Oraya Therapy uses low-energy, highly targeted X-rays to treat Wet AMD and is intended as a one-time procedure with the potential to maintain vision while reducing the required number of anti-VEGF injections into the eye. More >

Wednesday, August 20, 2014 | Sheffield Teaching Hospitals NHS Foundation Trust has become the first NHS hospital in the UK to start offering appropriate patients a new non-invasive treatment for wet age-related macular degeneration (wet AMD)…More >

Tuesday, August 5, 2014 | Oraya® Therapeutics, Inc. announced today that they have been awarded a $215,000 Small Business Technology Transfer Grant from the National Institutes of Health to investigate how Oraya Therapy, a low voltage stereotactic radiotherapy, and gold nanoparticles can further enhance the treatment of wet age-related macular degeneration (Wet AMD)…More >

Tuesday, July 22, 2014 | Oraya® Therapeutics, Inc. announced today that it is significantly expanding its presence in Europe, with Oraya Therapy being offered for the first time at a National Health Service hospital in the United Kingdom and at four prestigious university hospitals in Germany…More >

Latest News

October 6, 2014 | Mail Online: Health
Painless X-ray that can save failing eyes in 15 minutes.

October 1, 2014 | Fierce Medical Devices
Oraya Therapetics Named Among Fierce Medical Devices 2014 Fierce 15.

September 21, 2014 | Retinal Physician eUpdate
INTREPID Study of Oraya Therapy Continues to Show Favorable Safety Profile.

September 14, 2014 | Eyewire Today
Three-Year Data from Oraya Therapeutics’ INTREPID Study Continue to Show Favorable Safety Profile of Non-Invasive Wet AMD Therapy.

May 29, 2014 | San Francisco Business Times
Oraya Therapeutics named to San Francisco Business Times I-List — the 40-most innovative life science companies in the Bay Area.

Back To Top

© 2014 All rights reserved. Oraya Therapeutics, Inc. The IRay® is a CE-marked medical device. The IRay is not available for sale in the United States. For additional details, including safety and risk information, please see the ORAYA THERAPY section of this website. Oraya, Oraya Therapy, IRay and I-Guide are either trademarks or registered trademarks of Oraya Therapeutics, Inc. in the United States and other countries.